The Final Word on Ivermectin to Treat Covid



ORIGINAL POST
Posted by Ed 19 days ago
https://hongkong.asiaxpat.com/Utility/GetImage.ashx?ImageID=615722ee-c771-4549-b6c3-b3da23ed6043&refreshStamp=0

Please support our advertisers:
COMMENTS
Ed 19 days ago

Podcast king Joe Rogan threatened to sue CNN on a broadcast this week, saying that the network is constantly spreading lies about him taking Ivermectin, after CNN claimed that the medicine is horse de-wormer, when it is not.


https://youtu.be/3O_7O9_nV10
 

Please support our advertisers:
Ed 17 days ago
Ivermectin: Australian regulator bans drug as Covid treatment after sharp rise in prescriptions
 
Therapeutic Goods Administration concerned people taking controversial medication instead of seeking proper treatment or vaccine
 
https://www.theguardian.com/australia-news/2021/sep/10/australian-drug-regulator-bans-ivermectin-as-covid-treatment-after-sharp-rise-in-prescriptions 
 
 
'Sharp Rise in Prescriptions'   = doctors believe that Ivermectin can treat Covid.... 
 
Perhaps they have seen:
 
https://hongkong.asiaxpat.com/Utility/GetImage.ashx?ImageID=615722ee-c771-4549-b6c3-b3da23ed6043&refreshStamp=0 
 

Please support our advertisers:
Ed 17 days ago
https://youtu.be/dSgBVFAO73I 
 
https://youtu.be/gWkUD2xT134
 
 

Please support our advertisers:
Ed 16 days ago

Omar Khan interviews Dr. Harvey Risch of Yale University, epidemiologist, cancer researcher, advocate of COVID early treatment, on the clear, consistent corruption of credibility that is now truly “pandemic.”   Listen

 
 
Dr. Harvey Risch is Professor of Epidemiology in the Department of Epidemiology and Public Health at the Yale School of Public Health and Yale School of Medicine. Dr. Risch received his MD degree from the University of California San Diego and PhD from the University of Chicago.
 
After serving as a postdoctoral fellow in epidemiology at the University of Washington, Dr. Risch was a faculty member in epidemiology and biostatistics at the University of Toronto before coming to Yale. Dr. Risch's research interests are in the areas of cancer etiology, prevention and early diagnosis, and in epidemiologic methods.
 
He is especially interested in the effects of reproductive factors, diet, genetic predisposition, histopathologic factors, occupational/environmental/medication exposures, infection and immune functioning in cancer etiology. His major research projects have included studies of ovarian cancer, pancreas cancer, lung cancer, bladder cancer, esophageal and stomach cancer, and of cancers related to usage of oral contraceptives and noncontraceptive estrogens.
 
Dr. Risch is Associate Editor of the Journal of the National Cancer Institute, Editor of the International Journal of Cancer, and was for six years a Member of the Board of Editors, the American Journal of Epidemiology.
 
Dr. Risch is an author of more than 350 original peer-reviewed research publications in the medical literature and those research papers have been cited by other scientific publications more than 44,000 times. Dr. Risch has an h-index of 94 and is a Member of the Connecticut Academy of Sciences and Engineering.

Please support our advertisers:
Ed 8 days ago
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines
 
Bryant, Andrew MSc1,*; Lawrie, Theresa A. MBBCh, PhD2; Dowswell, Therese PhD2; Fordham, Edmund J. PhD2; Mitchell, Scott MBChB, MRCS3; Hill, Sarah R. PhD1; Tham, Tony C. MD, FRCP4
 
Abstract
 
Background:
 
Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials.

Areas of uncertainty:
 
We assessed the efficacy of ivermectin treatment in reducing mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection.

Data sources:
 
We searched bibliographic databases up to April 25, 2021. Two review authors sifted for studies, extracted data, and assessed risk of bias. Meta-analyses were conducted and certainty of the evidence was assessed using the GRADE approach and additionally in trial sequential analyses for mortality. Twenty-four randomized controlled trials involving 3406 participants met review inclusion.

Therapeutic Advances:
 
Meta-analysis of 15 trials found that ivermectin reduced risk of death compared with no ivermectin (average risk ratio 0.38, 95% confidence interval 0.19–0.73; n = 2438; I2 = 49%; moderate-certainty evidence). This result was confirmed in a trial sequential analysis using the same DerSimonian–Laird method that underpinned the unadjusted analysis. This was also robust against a trial sequential analysis using the Biggerstaff–Tweedie method. Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% (95% confidence interval 79%–91%). Secondary outcomes provided less certain evidence. Low-certainty evidence suggested that there may be no benefit with ivermectin for “need for mechanical ventilation,” whereas effect estimates for “improvement” and “deterioration” clearly favored ivermectin use. Severe adverse events were rare among treatment trials and evidence of no difference was assessed as low certainty. Evidence on other secondary outcomes was very low certainty.

Conclusions:
 
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
 
https://journals.lww.com/americantherapeutics/fulltext/2021/08000/ivermectin_for_prevention_and_treatment_of.7.aspx



Please support our advertisers:

< Back to main category



Login now